




Truenat[®] CT/NG

Chip-based Real-Time Duplex
PCR Test for *Chlamydia Trachomatis*
and *Neisseria Gonorrhoea*



Silent Infections, Lasting Consequences



Sexually transmitted infections (STIs) continue to pose a significant global health burden.

WHO estimates

1 million

new infections each day

approximately

374 million

curable cases annually,
primarily from

Chlamydia

Gonorrhoea

Trichomoniasis


Syphilis



Chlamydia and *gonorrhoea* together account for the highest global prevalence among curable bacterial STIs.


Women are disproportionately affected by these infections.

Global Burden



129 million

new cases of chlamydia



82 million

new cases of gonorrhoea

were detected among adolescents and adults
aged 15–49 years worldwide annually.*

(*as per the 2020 data)

The Prevalent Diagnostic Challenge

In low- and middle-income countries (LMICs), STI care still relies on syndromic management — an approach that often misses asymptomatic infections and leads to over or under-treatment, as highlighted by the WHO.

The WHO identifies Nucleic Acid Amplification Tests (NAATs) as the gold standard for detecting *C. trachomatis* and *N. gonorrhoeae*, offering high accuracy and reliability even in asymptomatic people.²

Yet, access to NAAT remains largely centralized, resulting in delays, logistical challenges, and patients lost to follow-up.

BRIDGE THE GAP WITH Truenat[®] CT/NG

The Truenat[®] CT/NG Assay delivers WHO-aligned, point-of-care molecular testing for simultaneous detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*.



A chip-based real-time duplex quantitative PCR test on the Truenat[®] platform delivers accurate results in under 60 minutes, enabling rapid diagnosis right at the primary healthcare level.

Decentralising Diagnosis with Truenat[®]

Alignment with WHO's diagnostic recommendations:

- Move from syndromic to etiological diagnosis
- Support same-day testing and treatment for improved outcomes
- Integrate STI testing at the primary care level

Ideal for deployment in varied settings:



District and community clinics



Youth and sexual health centres



Antenatal care programs



Prisons, defence facilities, and outreach setups

KEY FEATURES



<1 hour turnaround time



Reagent stability

Room temperature stable reagents



User-friendly

Requires minimal human resource training



**Lyophilized, ready-to-use
PCR reagents**



Smart chip

Replete with batch-specific data



Minimal biosafety requirements

Can be used even in resource limited settings

ORDERING INFORMATION

Pack Size	5T	20T	25T	50T
Cat. No.	601160005	601160020	601160025	601160050

REFERENCE

¹ World Health Organization. Updated Recommendations for the Treatment of *Neisseria gonorrhoeae*, *Chlamydia trachomatis* and *Treponema pallidum* (Syphilis). Geneva: WHO, 2024. (Section 1.1, Epidemiology and Global Targets, p. 2)

² World Health Organization. Laboratory and Point-of-Care Diagnostic Testing for Sexually Transmitted Infections, including HIV. Geneva: WHO, 2023.



MOLBIO DIAGNOSTICS LIMITED
L-46, Phase II D, Verna Industrial Estate,
Verna, Goa - 403722, India



+91 8326724888



sales@molbiodiagnostics.com



www.molbiodiagnostics.com



customersupport@molbiodiagnostics.com